Jacob Johnson
Stock Analyst at Stephens & Co.
(2.84)
# 1,628
Out of 5,124 analysts
78
Total ratings
45.76%
Success rate
8.57%
Average return
Main Sectors:
Stocks Rated by Jacob Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| STE STERIS | Reiterates: Overweight | $240 | $253.52 | -5.33% | 7 | Feb 6, 2025 | |
| MASS 908 Devices | Reiterates: Overweight | $6 | $5.25 | +14.29% | 4 | Jan 15, 2025 | |
| LFCR Lifecore Biomedical | Reiterates: Equal-Weight | $6 | $8.18 | -26.65% | 5 | Jan 3, 2025 | |
| AZTA Azenta | Reiterates: Overweight | $60 | $33.26 | +80.40% | 6 | Jan 2, 2025 | |
| DHR Danaher | Reiterates: Overweight | $315 | $228.92 | +37.60% | 2 | Oct 23, 2024 | |
| TMO Thermo Fisher Scientific | Initiates: Overweight | $680 | $579.45 | +17.35% | 1 | Oct 1, 2024 | |
| RGEN Repligen | Reiterates: Overweight | $170 | $163.86 | +3.75% | 4 | Jul 30, 2024 | |
| TKNO Alpha Teknova | Reiterates: Overweight | $5 | $3.80 | +31.58% | 5 | Jul 10, 2024 | |
| MXCT MaxCyte | Reiterates: Overweight | $11 | $1.55 | +609.68% | 5 | Apr 23, 2024 | |
| STVN Stevanato Group | Reiterates: Overweight | $38 | $20.12 | +88.87% | 2 | Mar 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $17 | $9.60 | +77.08% | 3 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Equal-Weight | $2.5 | $2.06 | +21.36% | 3 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $92 → $87 | $58.81 | +47.93% | 10 | Feb 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $420 → $390 | $275.14 | +41.75% | 8 | Oct 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $16 → $18 | $11.76 | +53.06% | 5 | Aug 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $6 | $1.63 | +268.10% | 2 | Jul 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $27 → $29 | $24.18 | +19.93% | 3 | Jul 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $153 → $130 | $188.97 | -31.21% | 2 | May 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $377 | $199.48 | +88.99% | 1 | Apr 7, 2022 |
STERIS
Feb 6, 2025
Reiterates: Overweight
Price Target: $240
Current: $253.52
Upside: -5.33%
908 Devices
Jan 15, 2025
Reiterates: Overweight
Price Target: $6
Current: $5.25
Upside: +14.29%
Lifecore Biomedical
Jan 3, 2025
Reiterates: Equal-Weight
Price Target: $6
Current: $8.18
Upside: -26.65%
Azenta
Jan 2, 2025
Reiterates: Overweight
Price Target: $60
Current: $33.26
Upside: +80.40%
Danaher
Oct 23, 2024
Reiterates: Overweight
Price Target: $315
Current: $228.92
Upside: +37.60%
Thermo Fisher Scientific
Oct 1, 2024
Initiates: Overweight
Price Target: $680
Current: $579.45
Upside: +17.35%
Repligen
Jul 30, 2024
Reiterates: Overweight
Price Target: $170
Current: $163.86
Upside: +3.75%
Alpha Teknova
Jul 10, 2024
Reiterates: Overweight
Price Target: $5
Current: $3.80
Upside: +31.58%
MaxCyte
Apr 23, 2024
Reiterates: Overweight
Price Target: $11
Current: $1.55
Upside: +609.68%
Stevanato Group
Mar 25, 2024
Reiterates: Overweight
Price Target: $38
Current: $20.12
Upside: +88.87%
Mar 13, 2024
Reiterates: Equal-Weight
Price Target: $17
Current: $9.60
Upside: +77.08%
Mar 7, 2024
Reiterates: Equal-Weight
Price Target: $2.5
Current: $2.06
Upside: +21.36%
Feb 2, 2024
Maintains: Overweight
Price Target: $92 → $87
Current: $58.81
Upside: +47.93%
Oct 27, 2023
Maintains: Overweight
Price Target: $420 → $390
Current: $275.14
Upside: +41.75%
Aug 21, 2023
Upgrades: Overweight
Price Target: $16 → $18
Current: $11.76
Upside: +53.06%
Jul 21, 2023
Reiterates: Overweight
Price Target: $6
Current: $1.63
Upside: +268.10%
Jul 17, 2023
Maintains: Overweight
Price Target: $27 → $29
Current: $24.18
Upside: +19.93%
May 16, 2022
Maintains: Overweight
Price Target: $153 → $130
Current: $188.97
Upside: -31.21%
Apr 7, 2022
Initiates: Overweight
Price Target: $377
Current: $199.48
Upside: +88.99%